Evidence map›Paper›PMID 42039196›Full record

ArticleFrontiers in immunology2026

PhIP-driven prostate cancer involves key molecular regulators and immune microenvironment modulation.

Yaoan Wen, Jiangbin Yang, Yuzhe Su, Shaoyuan Chen, Song Zheng, Shaoxing Zhu, Guoqiang Chen, Shuyuan Zhan

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yaoan Wen *Department of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Jiangbin Yang *Department of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Yuzhe Su *Department of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Shaoyuan ChenDepartment of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Song ZhengDepartment of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Shaoxing ZhuDepartment of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
Guoqiang ChenDepartment of Urology, The Second Hospital of Longyan, Longyan, Fujian, China.
Shuyuan ZhanDepartment of Urology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Exposure to 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) may promote the initiation and progression of prostate cancer (PCa); however, its precise molecular mechanisms remain unclear. Methods: By integrating network toxicology, bioinformatics, and machine learning algorithms, potential molecular targets of PhIP in PCa were identified. Their biological significance was comprehensively evaluated through immune infiltration analysis, single-cell analysis, high-precision molecular docking, molecular dynamics simulations, and experimental validation. Results: A total of 17 candidate genes associated with PhIP-induced PCa were identified. SHAP analysis identified SLC14A1 as the dominant contributor to model performance. Molecular docking and molecular dynamics simulations suggested that PhIP could form a stable, high-affinity complex with SLC14A1. Experimental validation showed that PhIP exposure induced cytotoxicity and was associated with decreased SLC14A1 expression, while immune infiltration and single-cell analyses further indicated its close association with the tumor immune microenvironment and epithelial localization. Conclusion: This study offers valuable insights into the potential risks of PhIP exposure in PCa. The key genes and pathways identified may serve as potential biomarkers and therapeutic targets, providing new directions for future research and public health strategies.

Indexed as

ImidazolesProstatic NeoplasmsTumor MicroenvironmentAnimalsComputational BiologyGene Expression Regulation, NeoplasticHumansMaleMolecular Docking SimulationMolecular Dynamics SimulationImidazolesbioinformaticsmachine learningmolecular dockingPhIPprostate cancertumor microenvironment

Identifiers

PMID42039196
PMCPMC13106171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.